Results 21 to 30 of about 16,181 (154)

Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial

Frontiers in Pharmacology, 2021
Background: Ticagrelor monotherapy after 3 months dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).
Kyeong Ho Yun, Jae Young Cho, Seung Yul Lee, Sang Jae Rhee, Byeong Keuk Kim, Myeong Ki Hong, Yangsoo Jang, Seok Kyu Oh, the TICO Investigators   +8 more
doaj   +1 more source

Appropriateness of Ticagrelor Use at Initiation: A Population-Based Cohort Study

Journal of Pharmacy & Pharmaceutical Sciences, 2018
Purpose. Ticagrelor is recommended following an acute coronary syndrome if used appropriately. Its use has not yet been well described in the context of ambulatory clinical practice.
Jean-Pierre Gregoire, Paul Poirier, Norma Pérez, Éric Demers, Jocelyne Moisan   +4 more
doaj   +1 more source

Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice

Molecules, 2021
Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked to the development of dyspnea ...
Jennifer Lagoutte-Renosi, Bernard Royer, Vahideh Rabani, Siamak Davani   +3 more
doaj   +1 more source

Novel cancer-fighting role of ticagrelor inhibits GTSE1-induced EMT by regulating PI3K/Akt/NF-κB signaling pathway in malignant glioma

Heliyon
Background: Glioma is the most common malignant brain tumor of the central nervous system. Despite of the improvement of therapeutic strategy, the prognosis of malignant glioma patients underwent by STUPP strategy is still unexpected.
Enzhou Lu, Boxian Zhao, Chao Yuan, Yanchao Liang, Xiaoxiong Wang, Guang Yang   +5 more
doaj   +1 more source

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population [PDF]

PeerJ
Background Ticagrelor is a novel oral antiplatelet agent which can selectively inhibit P2Y12 receptor. Bleeding and dyspnea are common adverse reactions of ticagrelor in clinic.
Xiaoxia Hu, Peng Wang, Dali Zeng, Guo-xin Hu   +3 more
doaj   +2 more sources

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes versus ...
Giulia Magnani, Diego Ardissino, KyungAh Im, Andrzej Budaj, Robert F. Storey, P. Gabriel Steg, Deepak L. Bhatt, Marc Cohen, Ton Oude Ophius, Assen Goudev, Alexander Parkhomenko, Gabriel Kamensky, Dominick J. Angiolillo, José López‐Sendón, Per Johanson, Eugene Braunwald, Marc S. Sabatine, Marc P. Bonaca   +17 more
doaj   +1 more source

Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. [PDF]

PLoS ONE, 2015
In patients with myocardial infarction, ticagrelor reduces cardiovascular and sepsis-related mortality, and can cause dyspnea. It is suggested that this is caused by adenosine receptor stimulation, because in preclinical studies, ticagrelor blocks the ...
T N A van den Berg, S El Messaoudi, G A Rongen, P H H van den Broek, A Bilos, A R T Donders, M E Gomes, N P Riksen   +7 more
doaj   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

Coronary Perforation During Excimer Laser Angioplasty in a Patient With Prior Thoracic Radiotherapy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Management of heavily calcified coronary lesions remains challenging despite advances in plaque‐modifying technologies. Excimer laser coronary angioplasty (ELCA) is an effective adjunctive strategy with a low risk of no‐reflow. Case Summary A 75‐year‐old woman with non–ST‐segment elevation acute coronary syndrome and severe left ...
Francesco Maria Sparasci, Alessandro Cafaro, Dionigi Fischetti, Alessandro Mandurino‐Mirizzi   +3 more
wiley   +1 more source

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats

Pharmaceutics, 2019
Tadalafil is a cytochrome P450 (CYP) 3A4 substrate. Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors.
Young-Guk Na, Jin-Ju Byeon, Hyun Wook Huh, Min-Ki Kim, Young G. Shin, Hong-Ki Lee, Cheong-Weon Cho   +6 more
doaj   +1 more source